Examining miR-196a, miR-196b and NF-κBIα gene expression in colitis mice model

Area of Science:

• Microbiology
• Immunology
• Gastroenterology

Background:

• Inflammatory Bowel Disease (IBD) is a chronic condition characterized by gut inflammation.
• Bifidobacterium bifidum (B. bifidum) possesses anti-inflammatory properties and can modulate gut microbiota, suggesting therapeutic potential for IBD.

Purpose of the Study:

• To investigate the effects of B. bifidum on gene expression (miR-196a, miR-196b, NF-κBIα) in a dextran sulfate sodium (DSS)-induced IBD mouse model.
• To evaluate the therapeutic efficacy of B. bifidum in mitigating IBD-related inflammation and pathological changes.

Main Methods:

• Induction of colitis in male C57BL/6 mice using 3% DSS.
• Administration of B. bifidum via oral gavage to treatment groups.
• Monitoring of Disease Activity Index (DAI), body weight, colon length, spleen weight, and histological analysis of colon tissues.
• Quantification of inflammatory cytokines (TNF-α, IL-6) using ELISA and gene expression analysis (miR-196a, miR-196b, NF-κBIα) via RT-PCR.

Main Results:

• B. bifidum treatment led to weight gain and reduced colon and spleen weights compared to the untreated colitis group.
• Histopathological examination showed reduced mucosal damage and significant healing in B. bifidum-treated mice.
• B. bifidum significantly decreased levels of IL-6 and TNF-α and modulated the expression of miR-196a, miR-196b, and NF-κBIα genes.

Conclusions:

• B. bifidum exhibits significant anti-inflammatory effects in a DSS-induced IBD mouse model.
• The therapeutic benefits are associated with the modulation of miRNA expression and reduction of key inflammatory cytokines.
• B. bifidum represents a promising probiotic treatment strategy for IBD.